Restricted accessResearch articleFirst published online 2016-04
Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
Determining to what extent biophysical characteristics of aggregates affect immunogenicity of therapeutic interferon beta-1b. Three recombinant human interferon beta-1b (rhIFNβ-1b) samples with different levels of aggregates generated by copper oxidation, thermal stress, or left untreated, as well as Avonex® drug substance and Betaferon® drug product, were injected intraperitoneally in nontransgenic and interferon beta transgenic FVB/N mice 5 times per week for 3 weeks. Antibodies against interferon beta were measured using enzyme-linked immunosorbent assay. UV and fluorescence spectroscopy, dynamic light scattering, size exclusion chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), fluid imaging microscopy, and resonant mass measurement, as well as sodium dodecyl sulfate–polyacrylamide gel electrophoresis and Western blotting, were used to characterize and quantitate aggregates in the 3 rhIFNβ preparations, to correlate biophysical characteristics with immunogenicity. In immune-tolerant interferon beta transgenic FVB/N mice, Betaferon drug product showed the highest immunogenicity, while Avonex drug substance showed the lowest level of immunogenicity. Of the 3 forms of rhIFNβ-1b, copper-oxidized rhIFNβ-1b showed lower immunogenicity than thermally stressed rhIFNβ-1b, despite containing larger aggregates. Both copper-oxidized rhIFNβ-1b and thermally stressed rhIFNβ-1b exhibited changes in protein structure as shown using fluorescence spectroscopy and RP-HPLC. Nontransgenic, nonimmune-tolerant FVB/N mice generated high antibody titers against all interferon beta samples tested. The level of immunogenicity and the breaking of tolerance in FVB/N transgenic mice are not only related to the level of aggregation but also depend on the size and structure of the aggregates.
Get full access to this article
View all access options for this article.
References
1.
BarnardJG, BabcockK, CarpenterJF. 2012. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci, 3(102):915–927.
2.
BraunA, KweeL, LabowMA, AlsenzJ. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res, 14:1472–1478.
3.
BrownL. 2011. Characterizing biologics using dynamic imaging particle analysis. Bio Pharm Int, 24(8):s4–s9.
4.
BurgTP, GodinM, KnudsenSM, ShenW, CarlsonG, FosterJS, et al.2007. Weighing of biomolecules, single cells and single nanoparticles in fluid. Nature, 446:1066–1069.
5.
de VriesMK, BrouwerE, van der Horst-BruinsmaIE, SpoorenbergA, van DenderenJC, JamnitskiA, et al.2009. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation, Ann Rheum Dis, 68:1787–1788.
6.
den EngelsmanJ, GaridelP, SmuldersR, KollH, SmithB, BassarabS, et al.2011. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res, 28:920–933.
7.
FanH, RalstonJ, DibiaseM, FaulknerE, MiddaughCR. 2005. Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. J Pharm Sci, 94:1893–1911.
8.
FilipeV, HaweA, SchellekensH, JiskootW. 2010. Aggregation and immunogenicity of therapeutic proteins. In: WangW, RobertsCJ, eds. Aggregation of therapeutic proteins. Hoboken, NJ: John Wiley & Sons, Inc. pp 403–433.
9.
FilipeV, PooleR, OladunjoyeO, BraeckmansK, JiskootW. 2012. Detection and characterization of subvisible aggregates of monoclonal IgG in serum. Pharm Res, 29:2202–2212.
10.
GeigertJ, PanscharBM, FongS, HustonHN, WongDE, WongDY, et al.1988. The long-term stability of recombinant (serine-17) human interferon-β. J Interferon Res, 8:539–547.
11.
Haji AbdolvahabM, BrinksV, SchellekensH. 2014a. A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta. J Immunol Methods, 415:17–23.
12.
Haji AbdolvahabM, FazeliA, FazeliMR, BrinksV, SchellekensH. 2014b. The effects of dodecyl maltoside and sodium dodecyl sulfate surfactants on the stability and aggregation of recombinant interferon beta-1b. J Interferon Cytokine Res, 34(11):894–901.
13.
HaweA, FriessW. 2008. Development of HSA-free formulations for a hydrophobic cytokine with improved stability. Eur J Pharm Biopharm, 68:169–182.
14.
HermelingS, JiskootW, CrommelinDJA, BornæsC, SchellekensH. 2005a. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res, 22:847–851.
15.
HermelingS, AranhaL, DamenJMA, SlijperM, SchellekensH, CrommelinDJA, et al.2005b. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res, 22:1997–2006.
16.
HermelingS, SchellekensH, MaasC, GebbinkMFBG, CrommelinDJA, JiskootW. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci, 95(5):1084–1096.
17.
HochuliE. 1997. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J. Interferon Cytokine Res, 17 (Suppl. 1):S15–S21.
18.
IshibashiM, TsumotoK, TokunagaM, EjimaD, KitaY, ArakawaT. 2005. Is arginine a protein-denaturant?. Protein Expr Purif, 42:1–6.
19.
KagawaY, TakasakiS, UtsumiJ, HosoiK, ShimizuH, et al.1988. Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. J Biol Chem, 263:17508–17515.
20.
KarpusasM, NolteM, BentonCB, MeierW, LipscombWN, GoelzS. 1997. The crystal structure of human interferon-beta at 2.2-Å resolution. Proc Natl Acad Sci U S A, 94:11813–11818.
21.
KarpusasM, WhittyA, RunkelL, HochmanP. 1998. The structure of human interferon-beta: implications for activity. Cell Mol Life Sci, 54:1203–1216.
22.
KimHJ, ShinCH, KimCW. 2009. Stabilization of glycol protein liquid formulation using arginine: a study with lactoferrin as a model protein. Biosci Biotechnol Biochem, 73(1):61–66.
23.
KueltzoLA, MiddaughCR. 2005. Ultraviolet absorption spectroscopy. In: JiskootW, CrommelinDJA, eds. Methods for structural analysis of protein pharmaceuticals, vol III. Arlington, VA: AAPS. pp 1–25.
24.
LamXM, YangJY, ClelandJL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci, 86:1250–1255.
25.
LiS, NguyenTH, SchoneichC, BorchardtRT. 1995. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry, 34:5762–5772.
26.
MooreWV, LeppertP. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab, 51:691–697.
27.
PatroSY, FreundE, ChangBS. 2002. Protein formulation and fill-finish operations. Biotechnol Annu Rev, 8:55–84.
28.
RifkinRF, MaggioET, DikeS, KerrDA, LevyM. 2011. n-Dodecyl-β-d-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity. J Neuroimmune Pharmacol, 6:158–162.
29.
RosenbergAS. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J, 8:E501–E507.
30.
RunkelL, deDiosC, KarpusasM, BetzenhauserM, MuldowneyC, ZafariM, et al.2000. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. Biochemistry, 39:2538–2551.
31.
RunkelL, MeierW, PepinskyRB, KarpusasM, WhittyA, KimballK, et al.1998. Structural and functional differences between glycosylated and non-glycoslated forms of human interferon beta (IFN-beta). Pharm Res, 15:641–649.
32.
SchellekensH. 2002. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther, 24:1720–1740.
33.
SchernthanerG. 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care, 16 (Suppl. 3):155Y165.
34.
ShacterE. 2000. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev, 32:307–326.
35.
SharmaB. 2007. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol Adv, 25:310–317.
36.
SharmaDK, KingD, OmaP, MerchantC. 2010. Micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations. AAPS J, 12:455–464.
37.
ShirleyBA, BabukaS, ChenBL, HoraM, ChoeM, TellerM. 2008. HSA-free formulations of interferon-beta. Patent No. US 7:399–463 B2.
38.
SolaRJ, GriebenowK. 2009. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci, 98:1223–1245.
39.
TurroNJ, KuoPL, SomasundaranP, WongtK. 1986. Surface and bulk interactions of ionic and nonionic surfactants. J Phys Chem, 90:288–291.
40.
van BeersMMC, JiskootW, SchellekensH. 2010a. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res, 30:767–775.
41.
van BeersMMC, SauerbornM, GilliF, BrinksV, SchellekensH, JiskootM. 2010b. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res, 482(27):1812–1824.
42.
van BeersMMC, SauerbornM, GilliF, BrinksV. SchellekensH, JiskootW. 2011. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res, 28:2393–2402.
43.
van BeersMMC, SauerbornM, GilliF, HermelingS, SchellekensH, JiskootW. 2010c. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods, 352:32–37.
44.
WalkerJM. 2002. SDS polyacrylamide gel electrophoresis of proteins. In: WalkerJM, ed. The protein protocols handbook. Totowa, NJ: Humana Press, Inc. pp 61–67.
45.
WolbinkGJ, AardenLA, DijkmansBA. 2009. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol, 21:211–215.
